Table 1.
Clinical and laboratory characteristics of the patients
| Parameter | All patients (n = 75) | Continuation (n = 34) | Interruption (n = 41) | p value |
|---|---|---|---|---|
| Age, yr | 72.7 ± 5.0 | 72.3 ± 4.9 | 73.1 ± 5.2 | 0.843 |
| 65–69 | 17 (22.7) | 10 (29.4) | 7 (17.1) | 0.289 |
| 70–74 | 35 (46.7) | 12 (35.3) | 23 (56.0) | |
| 75–79 | 16 (21.3) | 9 (26.5) | 7 (17.1) | |
| 80–84 | 5 (6.6) | 3 (8.8) | 2 (4.9) | |
| 85–89 | 2 (2.7) | 0 | 2 (4.9) | |
| Sex | 0.908 | |||
| Male | 48 (64.0) | 22 (64.7) | 26 (63.4) | |
| Female | 27 (36.0) | 12 (35.3) | 15 (36.6) | |
| Body mass index, kg/m2 | 0.101 | |||
| < 23 | 43 (57.3) | 16 (47.1) | 27 (65.9) | |
| ≥ 23 | 32 (42.7) | 18 (52.9) | 14 (34.1) | |
| Weight loss in past 6 months | 0.108 | |||
| No | 55 (73.3) | 28 (82.3) | 27 (65.9) | |
| Yes | 20 (26.7) | 6 (17.7) | 14 (34.1) | |
| ECOG PS | 0.811 | |||
| 0/1 | 69 (92.0) | 31 (91.2) | 38 (92.7) | |
| 2 | 6 (8.0) | 3 (8.8) | 3 (7.3) | |
| Smoking | 0.094 | |||
| Nonsmoker | 34 (45.3) | 12 (35.2) | 22 (53.7) | |
| Ex- or current-smoker | 37 (49.4) | 18 (53.0) | 19 (46.3) | |
| Missing | 4 (5.3) | 4 (11.8) | 0 | |
| Educational level | 0.803 | |||
| Elementary school or less | 40 (53.3) | 18 (47.4) | 25 (56.8) | |
| Middle/high school graduate | 31 (41.3) | 18 (47.4) | 16 (36.4) | |
| Bachelor’s degree or higher | 2 (2.7) | 1 (2.6) | 2 (4.5) | |
| Missing | 2 (2.7) | 1 (2.6) | 1 (2.3) | |
| Religion | 0.559 | |||
| No | 46 (61.3) | 22 (64.7) | 24 (58.5) | |
| Yes | 29 (38.7) | 12 (35.5) | 17 (41.5) | |
| No. of comorbidities | 0.491 | |||
| 0 | 22 (29.3) | 10 (29.4) | 12 (29.3) | |
| 1 or 2 | 48 (64.0) | 23 (67.6) | 25 (61.0) | |
| 3 or more | 5 (6.7) | 1 (3.0) | 4 (9.7) | |
| Cancer type | 0.435 | |||
| Gastrointestinal | 21 (28.0) | 10 (29.4) | 11 (26.7) | |
| Lung/head and neck | 16 (21.3) | 7 (20.6) | 9 (22.0) | |
| Pancreaticobiliary | 17 (22.7) | 5 (14.7) | 12 (29.3) | |
| Genitourinary | 11 (14.7) | 7 (20.6) | 4 (9.8) | |
| Others | 10 (13.3) | 5 (14.7) | 5 (12.2) | |
| No. of distant metastases | 0.033a | |||
| 0 or 1 | 50 (66.7) | 27 (79.4) | 23 (58.5) | |
| 2 or more | 25 (33.4) | 7 (20.6) | 18 (41.5) | |
| Cytotoxic chemotherapy | 0.111 | |||
| Monochemotherapy | 20 (26.6) | 6 (17.6) | 14 (34.1) | |
| Polychemotherapy | 55 (73.4) | 28 (82.4) | 27 (65.9) | |
| Hemoglobin, g/dL | 11.4 ± 1.8 | 11.6 ± 1.9 | 11.2 ± 1.7 | 0.398 |
| White blood cell, 103/mm3 | 8.3 ± 4.7 | 8.3 ± 5.5 | 8.2 ± 3.9 | 0.925 |
| Platelet, 103/mm3 | 267 ± 88 | 282 ± 92 | 255 ± 84 | 0.199 |
| Albumin, g/dL | 3.4 ± 0.5 | 3.5 ± 0.4 | 3.2 ± 0.6 | 0.047a |
| GFR, mL/min/1.73m2 | 76.8 ± 20.6 | 73.5 ± 17.0 | 81.2 ± 22.5 | 0.064 |
| LDH, U/L | 562.6 ± 324.8 | 512.1 ± 272.5 | 604.4 ± 360.6 | 0.211 |
| CRP, mg/dL | 3.1 ± 3.9 | 2.6 ± 3.2 | 3.5 ± 4.5 | 0.343 |
| D-dimer, mg/L | 3.5 ± 3.9 | 2.9 ± 4.1 | 4.0 ± 3.7 | 0.241 |
Values are presented as mean ± SD or number (%).
ECOG PS, Eastern Cooperative Oncology Group performance status; GFR, glomerular filtration rate; LDH, lactate dehydrogenase; CRP, C-reactive protein.
a
Statistically significant (p < 0.05).